Aspirin-exacerbated respiratory disease and current treatment modalities

Basit Öğe Kaydı
dc.contributor.authorSakalar, Emine Guven
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorKar, Murat
dc.contributor.authorCingi, Cemal
dc.date.accessioned2020-06-25T18:23:10Z
dc.date.available2020-06-25T18:23:10Z
dc.date.issued2017
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs. AERD affects 0.3-0.9 % of the general population. AERD generally occurs due to abnormalities in mediators and expression of arachidonic acid biosynthesis. Local IgE responses to staphylococcal enterotoxins may also be responsible for eosinophilic activation in the nasal polyp tissues of AERD patients. Clinical features of AERD include the onset of nasal congestion with anosmia, progressing to chronic pansinusitis and nasal polyps that regrow rapidly after surgery. Aspirin desensitization, Leukotriene-modifying agents, biologic agents, management of asthma, chronic rhinosinusitis, and nasal polyposis are recommended as treatment modalities. Immunotherapy is prescribed only to those AERD patients who experience clear seasonal or perennial allergy symptoms in addition to the symptoms attributable to chronic nasal polyposis. There are also investigational and dietary therapies. In this review, the important aspects of AERD will be presented, along with a literature survey.en_US
dc.description.sponsorshipContinuous Education and Scientific Research Associationen_US
dc.description.sponsorshipThe preparation of this paper (including design and planning) was supported by the Continuous Education and Scientific Research Association.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s00405-016-4273-1
dc.identifier.endpage1300en_US
dc.identifier.issn0937-4477
dc.identifier.issn1434-4726
dc.identifier.issue3en_US
dc.identifier.pmid27538737
dc.identifier.scopus2-s2.0-84982272612
dc.identifier.scopusqualityQ1
dc.identifier.startpage1291en_US
dc.identifier.urihttps://doi.org/10.1007/s00405-016-4273-1
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7026
dc.identifier.volume274en_US
dc.identifier.wosWOS:000394350800013
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Archives Of Oto-Rhino-Laryngology
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAspirin-exacerbated respiratory disease (AERD)en_US
dc.subjectChronic rhinosinusitis with nasal polyposisen_US
dc.subjectAsthmaen_US
dc.subjectAspirin (acetylsalicylic acid, ASA)en_US
dc.subjectCyclooxygenase-1-inhibiting non-steroidal anti-inflammatory drugsen_US
dc.titleAspirin-exacerbated respiratory disease and current treatment modalitiesen_US
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Aspirin-exacerbated respiratory disease and current treatment modalities.pdf
Boyut:
625.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu